1. Home
  2. ADPT vs TNGX Comparison

ADPT vs TNGX Comparison

Compare ADPT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$27.73

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

N/A

Current Price

$21.96

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
TNGX
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.1B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
ADPT
TNGX
Price
$27.73
$21.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$33.86
★ $47.00
AVG Volume (30 Days)
2.1M
★ 3.6M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.89
26.89
EPS
★ N/A
N/A
Revenue
★ $276,976,000.00
$62,384,000.00
Revenue This Year
$10.85
N/A
Revenue Next Year
$21.60
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 54.77
48.29
52 Week Low
$12.00
$8.30
52 Week High
$32.21
$34.39

Technical Indicators

Market Signals
Indicator
ADPT
TNGX
Relative Strength Index (RSI) 49.06 44.62
Support Level $24.02 $20.49
Resistance Level $29.92 $22.01
Average True Range (ATR) 1.71 1.92
MACD -0.09 -0.15
Stochastic Oscillator 31.91 18.52

Price Performance

Historical Comparison
ADPT
TNGX

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: